Literature DB >> 7775138

Phase II study of edatrexate in advanced head and neck cancer. A Southwest Oncology Group study.

J P Kuebler1, J Benedetti, D E Schuller, J Ensley, S M Grunberg, M J Muirhead, K E Richert-Boe, M E Marshall.   

Abstract

Fifty-two patients with persistent, recurrent and/or metastatic squamous cell cancer of the head and neck were treated with weekly edatrexate, 80 mg/m2. Nine patients had received previous adjuvant or neoadjuvant chemotherapy. Of the 46 eligible patients, two complete responses and one partial response were observed (6%, 95% confidence interval of 1-18%). The most common toxicities were myelosuppression and mucositis, but dermatologic toxicity was also observed in 25% of patients. Edatrexate appears to have limited activity in advanced head and neck cancer.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7775138     DOI： 10.1007/bf00873052

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  7 in total

1.  Toxic dermatitis induced by 10-ethyl-10-deaza-aminopterin (10-EdAM), a novel antifolate.

Authors:  J Verweij; J Schornagel; P de Mulder; S Henzen-Logmans; F Cognetti; M Clavel; J Vermorken
Journal:  Cancer       Date:  1990-11-01       Impact factor: 6.860

2.  Phase II study of 10-EdAM in patients with squamous cell carcinoma of the head and neck, previously untreated with chemotherapy.

Authors:  M D Green; P Sherman; J Zalcberg
Journal:  Invest New Drugs       Date:  1992-04       Impact factor: 3.850

3.  Comparative study of the sensitivity of head and neck cell lines to methotrexate (MTX) and the analog 10-ethyl, 10-deazaaminopterin (10-EdAM).

Authors:  D H Brown; B J Braakhuis; G A Van Dongen; G B Snow
Journal:  Otolaryngol Head Neck Surg       Date:  1990-01       Impact factor: 3.497

4.  A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. The EORTC Head and Neck Cancer Cooperative Group.

Authors:  J H Schornagel; J Verweij; P H de Mulder; F Cognetti; J B Vermorken; P Cappelaere; J P Armand; J Wildiers; M Clavel; A Kirkpatrick
Journal:  Ann Oncol       Date:  1992-03       Impact factor: 32.976

5.  Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.

Authors:  A A Forastiere; B Metch; D E Schuller; J F Ensley; L F Hutchins; P Triozzi; J A Kish; S McClure; E VonFeldt; S K Williamson
Journal:  J Clin Oncol       Date:  1992-08       Impact factor: 44.544

6.  New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models.

Authors:  F M Sirotnak; J I DeGraw; F A Schmid; L J Goutas; D M Moccio
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice.

Authors:  F A Schmid; F M Sirotnak; G M Otter; J I DeGraw
Journal:  Cancer Treat Rep       Date:  1985-05
  7 in total
  1 in total

Review 1.  From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.

Authors:  Jackie Walling
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.651
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.